TrialThe Lancet. Oncology2021

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.

Per Fransson et al.PubMed ↗Publisher ↗

No numbers read from the abstract.